

February 8, 2021

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, February 8, 2021

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Monday, February 8, 2021 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2020. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 8, 2021 are enclosed herewith.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Pratap Rudra
Company Secretary & Legal Counsel



AstraZeneca Pharma India Limited
 Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
 Statement of unaudited financial results for the quarter and nine months ended 31 December 2020

| Sl No. | Particulars | 'Rs in lakhs except for earnings per share data | | | | | |
|--------|-----------------------------------------------------------------------------------|-------------------------------------------------|-------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------|
| | | 3 months ended 31/12/2020 Unaudited | Previous 3 months ended 30/09/2020 Unaudited | Corresponding 3 months ended in the previous year 31/12/2019 Unaudited | 9 months ended 31/12/2020 Unaudited | 9 months ended 31/12/2019 Unaudited | Year ended 31/03/2020 Audited |
| 1 | Revenue | | | | | | |
| | a) Revenue from operations | 20,025.20 | 20,947.71 | 22,386.28 | 60,330.67 | 63,680.72 | 63,180.91 |
| | b) Other income | 292.82 | 471.25 | 346.15 | 1,028.88 | 961.15 | 1,298.79 |
| | Total Income | 20,318.02 | 21,418.96 | 22,732.43 | 61,359.55 | 64,641.87 | 64,479.70 |
| 2 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 2,619.66 | 2,397.66 | 2,164.70 | 7,102.92 | 5,368.39 | 7,021.07 |
| | (b) Purchase of stock-in-trade | 2,135.03 | 6,929.50 | 7,675.58 | 13,775.75 | 18,701.43 | 27,423.30 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | 2,075.59 | (1,571.66) | (1,708.52) | 963.11 | (1,518.54) | (3,920.84) |
| | (d) Employee benefits expense | 5,505.53 | 5,564.47 | 5,255.49 | 16,704.75 | 15,545.25 | 21,670.07 |
| | (e) Depreciation expense | 511.04 | 462.20 | 477.12 | 1,429.40 | 1,403.91 | 1,868.36 |
| | (f) Allowance for expected credit loss (net) | 21.37 | 186.98 | 42.11 | 190.43 | 92.58 | 158.27 |
| | (g) Selling, marketing and distribution expense | 1,432.89 | 1,148.79 | 1,169.65 | 3,505.54 | 4,269.14 | 5,575.57 |
| | (h) Other expenses | 3,160.58 | 2,716.33 | 4,110.91 | 8,581.01 | 10,644.00 | 13,184.19 |
| | (i) Finance cost | 26.04 | 27.68 | 27.13 | 81.12 | 85.03 | 113.67 |
| | Total expenses | 17,487.93 | 17,861.97 | 19,214.18 | 52,334.03 | 54,591.09 | 73,083.66 |
| 3 | Profit before exceptional and extraordinary items and tax (1-2) | 2,830.09 | 3,556.99 | 3,518.26 | 9,025.52 | 10,060.78 | 11,396.04 |
| 4 | Exceptional items | - | - | - | - | - | - |
| 5 | Profit before extraordinary items and tax (3+4) | 2,830.09 | 3,556.99 | 3,518.26 | 9,025.52 | 10,060.78 | 11,396.04 |
| 6 | Extraordinary items | - | - | - | - | - | - |
| 7 | Profit before tax (5+6) | 2,830.09 | 3,556.99 | 3,518.26 | 9,025.52 | 10,060.78 | 11,396.04 |
| 8 | Tax expense | | | | | | |
| | - Current tax | 773.62 | 994.75 | 881.34 | 2,627.91 | 2,665.55 | 3,150.93 |
| | - Deferred tax | (48.69) | (71.60) | (33.25) | (204.85) | 1,132.00 | 1,024.02 |
| | Total tax expense | 724.93 | 923.16 | 848.09 | 2,423.06 | 3,797.55 | 4,174.95 |
| 9 | Profit after tax (7-8) | 2,105.16 | 2,633.84 | 2,670.16 | 6,602.46 | 6,263.23 | 7,221.09 |
| 10 | Other comprehensive Income/(loss) | | | | | | |
| | A. Items that will not be reclassified to profit or loss | | | | | | |
| | Re-measurement gains/(losses) on post employment benefit obligations | (5.20) | (4.27) | 107.26 | 88.71 | (351.63) | (657.70) |
| | Income tax effect on above | 1.31 | 1.08 | (27.00) | (22.33) | 88.50 | 165.53 |
| | Total other comprehensive Income/ (loss), net of income tax | (3.89) | (3.19) | 80.27 | 66.38 | (263.13) | (492.17) |
| | Total comprehensive income for the period (9+10) | 2,101.27 | 2,630.66 | 2,750.43 | 6,668.84 | 6,000.10 | 6,728.92 |
| 11 | Paid-up equity share capital (Face value of Rs 2/- per equity share) | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| 12 | Reserves (excluding revaluation reserves as per balance sheet) | - | - | - | - | - | 35,943.62 |
| 13 | Earnings per equity share of Rs 2/- each (basic and diluted) | 8.42 | 10.54 | 10.68 | 26.41 | 25.05 | 28.88 |

PRADIP M KANAKIA Digitally signed by PRADIP M KANAKIA
 Date: 2021.02.08 17:46:47 +05'30'

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter and nine months ended 31 December 2020

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 **Impact of COVID-19 Pandemic**
The Company, which is in the business of manufacture and supply of essential goods, has been assessing the impact of COVID-19 pandemic on its business and believes that the pandemic does not have a material impact on the current or future operations, financial position and liquidity of the Company. Management has considered all possible impact of known events arising from the pandemic in the preparation of these financial results and will continue to closely monitor the situation.
- 4 The Indian Parliament has approved the Code on Social Security, 2020 ("Code") which may likely impact the contributions made by the Company towards employee's provident fund and gratuity. The effective date from which the Code is applicable and the rules to be framed under the Code are yet to be notified. In view of this, impact of the change, if any, will be assessed and accounted in the period in which the Code and the rules thereunder are notified.
- 5 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 6 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 08 February 2021. The Statutory Auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2020.

**By Order of the Board of Directors
For AstraZeneca Pharma India Limited**



Gagandeep Singh Bedi
Managing Director

Place: Bengaluru
Date: 08 February, 2021

Price Waterhouse & Co Chartered Accountants LLP

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bengaluru – 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the “Company”) for the quarter ended December 31, 2020 and the year to date results for the period April 1, 2020 to December 31, 2020 which are included in the accompanying ‘Statement of unaudited financial results for the quarter and nine months ended 31 December 2020’ (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations, 2015”), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company’s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009

PRADIP M KANAKIA Digitally signed by PRADIP M
KANAKIA
Date: 2021.02.08 17:49:03 +05'30'

Pradip Kanakia
Partner
Membership Number: 039985
UDIN: 21039985AAAAAC3997

Place: Bengaluru
Date: February 8, 2021

*Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower ‘D’, The Millenia, 1 & 2 Murphy Road
Ulsoor, Bangalore-560 008
T: +91 (80) 4079 5000, F: +91 (80) 4079 5222*

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)